These High-Growth Stocks Were Down Over 50% This Year. Is It Time to Buy Them?
SoundHound AI is a leading voice technology company that just doubled its revenue over the year-ago quarter.
The Trade Desk stock tumbled earlier this year, but its first-quarter results sent the stock sharply higher.
10 stocks we like better than SoundHound AI ›
For investors that still have many years before retirement, growth stocks are one of the most efficient ways to increase their net worth. But the recent market sell-off is a good reminder that even the most promising companies can see their share prices fall in any given year.
But investors should never judge the investment merits of a business by its stock performance, since stocks can rise and fall for all kinds of reasons in the near term. A lot of the day-to-day movement in the markets is driven by traders who have a much shorter time frame for making money than retirement savers do.
SoundHound AI (NASDAQ: SOUN) and The Trade Desk (NASDAQ: TTD) are two growth stocks that fell hard this year. These companies just reported their first-quarter financial results. Let's look at what they reported, and whether it justifies at much lower prices than where they started 2025.
SoundHound AI has shown promising growth potential over the past few years. It is providing conversational voice technology powered by artificial intelligence (AI) to several leading restaurant brands and car companies.
After soaring last year to over $20, the stock has fallen 61% from those highs. But after the business just reported another quarter of strong growth, investors have to wonder if it's due for another rally.
Revenue grew 151% year over year in the first quarter. This growth was partly boosted by the acquisition of Amelia last year, which will extend the company's technology to new markets like healthcare and financial services. In the quarter, SoundHound unveiled Amelia 7.0, which will allow customers to use voice-enabled AI agents to automatically complete tasks without further instructions.
The company has been investing in voice technology for 20 years, and it has accumulated data from millions of conversations in dozens of languages. This is making its voice AI much smarter, potentially providing the company with a competitive advantage.
Its relationship with leading AI chip supplier Nvidia validates its capabilities. SoundHound's voice AI is integrated with Nvidia's AI Enterprise platform, which allows it to deliver faster processing and more responsive voice AI.
It's making great progress to grow its customer base. No single customer makes up more than 10% of its total revenue, which removes customer-concentration risk from the business.
However, SoundHound will still need to improve its profitability, as it reported a large adjusted net loss of $22 million on $29 million of revenue in the first quarter. The stock is also trading at an expensive valuation of 38 times trailing sales.
Overall, the company's growth, strategic acquisitions, and collaboration with Nvidia make it a mid-cap stock worth considering. If you're looking for a fast-growing company with huge upside potential in the AI market, SoundHound AI is an intriguing option. If the company can narrow its losses and continue to report high revenue growth, the stock could be a long-term winner.
In a year where there is a lot of uncertainty for the economy, marketers are looking for ways to boost the return on their ad spending, and many are increasingly turning to The Trade Desk, a leading digital ad-buying platform.
After the stock was cut in half earlier this year over a rare revenue miss in the fourth quarter, The Trade Desk returned with a strong quarter of growth to start 2025. The stock jumped after it reported revenue grew 25% over the year-ago quarter. It also notched a significant improvement in profits, with earnings per share surging 67% year over year.
The Trade Desk has been delivering high growth like this for several years. Its average annual revenue growth over the past 10 years is 49%, yet its platform has captured just 1% of total ad spending.
Investors are counting on its Kokai platform to drive more growth. Kokai uses AI to scan millions of ad impressions instantly to help ad buyers improve the effectiveness and return on their advertising investment. Management previously said it expected all clients to be using the platform by the end of this year.
Over the long term, The Trade Desk should benefit from people spending more time on platforms not owned by tech giants like Google, which controls a large portion of the digital ad market. Only around half of ad spending is going toward the open internet, while over half of Americans spend their time there. This is a big opportunity for The Trade Desk.
Analysts expect the company's earnings to grow at an annualized rate of 31% in the coming years. The stock isn't cheap, trading at 41 times expected earnings this year. But investors interested in the The Trade Desk's opportunity should take advantage of the recent dip, because this is about as fair of a valuation investors can expect for this quality growth stock.
Before you buy stock in SoundHound AI, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and SoundHound AI wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $614,911!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $714,958!*
Now, it's worth noting Stock Advisor's total average return is 907% — a market-crushing outperformance compared to 163% for the S&P 500. Don't miss out on the latest top 10 list, available when you join .
See the 10 stocks »
*Stock Advisor returns as of May 5, 2025
John Ballard has positions in Nvidia. The Motley Fool has positions in and recommends Nvidia and The Trade Desk. The Motley Fool has a disclosure policy.
These High-Growth Stocks Were Down Over 50% This Year. Is It Time to Buy Them? was originally published by The Motley Fool

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
S&P 500 Gains and Losses Today: Lululemon Stock Falls as Forecasts Reflect Consumer Caution
The S&P 500 added 1% on Friday, June 6, as a strong jobs report pointed to resilience in the labor market despite tariff-related concerns. After retreating from record highs over the past few sessions, shares of data analytics firm Palantir bounced back, boosted by a signal of robust AI demand. Shares of Lululemon plummeted after the apparel maker cut its outlook for the current quarter and the full year, citing soft consumer U.S. equities indexes pushed higher to close out the trading week. The Bureau of Labor Statistics reported that the U.S. economy added 139,000 jobs in May, topping economists' forecasts and helping alleviate concerns about a tariff-driven slowdown in the labor market. The S&P 500 gained 1% on Friday, closing above the 6,000-point level for the first time since February. The Dow was up 1.1%, while the Nasdaq jumped 1.2%. Shares of big data analytics software provider Palantir Technologies (PLTR) popped 6.5% higher, securing the top daily performance in the S&P 500. Positivity around its expanding government business helped lift Palantir to an all-time high on Tuesday, but before Friday's gains, the stock had been pulling back for a couple of sessions. Palantir and other artificial intelligence companies benefited from upbeat sentiment after earnings results from chipmaker Broadcom (AVGO) revealed strong AI demand. Moderna (MRNA) shares wrapped up a volatile week of trading with a gain of 5.1% on Friday. The biotech company announced at the end of last week that it had received Food and Drug Administration (FDA) approval for the use of its new COVID-19 vaccine by older and higher-risk patients. On Tuesday, Health and Human Services Secretary Robert F. Kennedy Jr. said Moderna had agreed to a placebo-controlled trial of the vaccine. United Airlines (UAL) announced a partnership with Spotify Technology (SPOT) that will allow airborne passengers to access playlists, audiobooks, and video podcasts from the streaming service on their seatback screens. United shares increased 4.8% on Friday, while rival carrier Delta Air Lines (DAL) shares were up 4.3%. Tesla (TSLA) shares advanced 3.7% on Friday as the feud between Tesla CEO Elon Musk and U.S. President Donald Trump showed signs of de-escalation heading into the weekend. The spat between the two contributed to a major drop in the electric vehicle (EV) maker's stock in the prior session. Several analysts reaffirmed their bullishness on Tesla despite the high-profile conflict, but they noted that the tensions with Trump could complicate the regulatory path for the firm's self-driving technology or risk alienating people with certain political perspectives. Lululemon Athletica (LULU) issued lower-than-expected sales and profit guidance for the current quarter and trimmed its full-year profit forecast. The maker of yoga attire and other athletic apparel noted that U.S. consumers are taking a cautious approach to spending and discussed plans to increase prices on some products as it aims to mitigate tariff impacts. Lululemon shares plunged 19.8% on Friday, dropping the most of any constituent in the S&P 500. JPMorgan and UBS analysts cut their price targets on Lululemon stock following the underwhelming outlook. Broadcom posted fiscal second-quarter sales and adjusted profit results that were roughly in line with consensus forecasts. A major year-over-year uptick in artificial intelligence semiconductor revenue helped the chipmaker achieve record quarterly revenue of $15 billion. However, Broadcom shares slipped 5% on Friday, receding from a string of record highs notched before the earnings release. Mosaic (MOS), a provider of fertilizers and other agricultural products, reduced its 2025 phosphate production guidance, citing operational issues at its U.S. facilities. Shares of Mosaic were down 4.4%. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
38 minutes ago
- Yahoo
Watch These Broadcom Stock Price Levels After Post-Earnings Slide
Broadcom shares fell sharply Friday, one day after the chip giant delivered results and an outlook that were largely in line with Wall Street estimates. Profit-taking had crept into the stock Thursday on the highest volume in around two months after the stock hit a record high this week, setting the stage for today's selling. The relative strength index recently climbed above 80, a reading that coincided with major tops in the stock in December and June last year. Investors should watch key support levels on Broadcom's chart around $235 and $200, while also monitoring an important overhead area near $ (AVGO) shares fell sharply Friday, one day after the chip giant delivered results and an outlook that were largely in line with Wall Street estimates. The company's shares hit a fresh record high this week ahead of its highly anticipated results, boosted by expectations of robust revenue growth driven by surging demand for chips that power generative AI technology. CEO Hock Tan told analysts on the company's earnings call that chip demand may accelerate during the second half of 2026 due to strong inference demand, referring to the process that uses a trained AI model to make predictions or decisions. Still, Broadcom shares fell 5% to around $247 on Friday as the results and outlook may have missed the lofty expectations of investors, especially after the blockbuster results delivered by rival Nvidia last week. With today's decline, Broadcom shares are up about 6% since the start of the year, slightly outpacing the performance of the S&P 500 index over that stretch. Let's break down the technicals on Broadcom's chart and identify key price levels worth watching out for. After plumbing a seven-month low in early April, Broadcom shares have trended sharply higher within a rising wedge, with the price testing the pattern's upper trendline in recent trading sessions. However, profit-taking crept into the stock Thursday on the highest volume in around two months, which set the stage for today's selling. It's also worth pointing out that the relative strength index recently climbed above 80, a reading that coincided with major tops in the stock in December and June last year. Let's identify key support levels on Broadcom's chart to watch amid the potential for further selling and also locate an important overhead area worth monitoring during recovery efforts in the stock. Coming into Friday's session, the $250 level found a confluence of support from the rising wedge pattern's lower trendline and three notable peaks that formed on the chart between December and January. With the stock closing below this level, shares could test the next lower level of support at $235. Investors may look for dip buying opportunities in this region near the February countertrend peak. Further selling could trigger a steeper drop to the psychological $200 area. The shares would likely encounter support in this location near the upward sloping 50-day moving average, which also closely aligns with the January swing low and a period on consolidation in mid-March. During recovery efforts in Broadcom shares, investors should monitor the $265 area. Tactical traders who buy earnings-driven weakness may decide to lock in profits near the stock's all-time high toward the rising wedge pattern's peak. The comments, opinions, and analyses expressed on Investopedia are for informational purposes only. Read our warranty and liability disclaimer for more info. As of the date this article was written, the author does not own any of the above securities. Read the original article on Investopedia
Yahoo
an hour ago
- Yahoo
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on June 2, 2025 (the 'Grant Date'), ORIC granted a total of 39,100 non-qualified stock options and 6,500 restricted stock units to three new non-executive employees who began their employment with ORIC in May 2025. These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient's continued employment or service through each applicable vesting date. The stock options have an exercise price equal to the closing price of ORIC's common stock on the Grant Date. Twenty-five percent (25%) of the shares subject to the stock options will vest on the one (1) year anniversary of the Grant Date, with one thirty-sixth (1/36th) of the remaining shares vesting each one-month period thereafter. One-third (1/3rd) of the restricted stock units will vest on each of the first three anniversaries of the Grant Date. The inducement grants are subject to the terms and conditions of the applicable stock option and restricted stock unit agreements and the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan. The inducement grants were approved by ORIC's Compensation Committee of the Board of Directors, as required by Nasdaq Rule 5635(c)(4), and were granted as a material inducement to employment in accordance with Nasdaq Rule 5635(c)(4). About ORIC Pharmaceuticals, Inc. ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients' lives by Overcoming Resistance In Cancer. ORIC's clinical stage product candidates include (1) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. Beyond these two product candidates, ORIC® is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to and follow us on X or LinkedIn. Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the vesting of the inducement grants; target indications for ORIC's product candidates; the potential advantages of ORIC's product candidates; and plans underlying ORIC's clinical trials and development. Words such as 'believes,' 'anticipates,' 'plans,' 'expects,' 'intends,' 'will,' 'goal,' 'potential' and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon ORIC's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as an early clinical stage company; ORIC's ability to develop, initiate or complete preclinical studies and clinical trials for, obtain approvals for and commercialize any of its product candidates; changes in ORIC's plans to develop and commercialize its product candidates; the potential for clinical trials of ORIC's product candidates to differ from preclinical, initial, interim, preliminary or expected results; negative impacts of health emergencies, economic instability or international conflicts on ORIC's operations, including clinical trials; the risk of the occurrence of any event, change or other circumstance that could give rise to the termination of ORIC's license and collaboration agreements; the potential market for our product candidates, and the progress and success of competing therapeutics currently available or in development; ORIC's ability to raise any additional funding it will need to continue to pursue its business and product development plans; regulatory developments in the United States and foreign countries; ORIC's reliance on third parties, including contract manufacturers and contract research organizations; ORIC's ability to obtain and maintain intellectual property protection for its product candidates; the loss of key scientific or management personnel; competition in the industry in which ORIC operates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled 'Risk Factors' in ORIC's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the 'SEC') on May 5, 2025, and ORIC's future reports to be filed with the SEC. These forward-looking statements are made as of the date of this press release, and ORIC assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Contact:Dominic Piscitelli, Chief Financial info@ sesión para acceder a tu cartera de valores